Bone marrow cell classification of erythroleukemia (M6) cases as well as cases with high level of expression ofTfR2-α messenger RNA
| Sample no. . | Diagnosis . | Expression (% K562) . | BM (%) . | |||
|---|---|---|---|---|---|---|
| TfR2-α . | TfR2-β . | TfR1 . | Blast . | Erythroid . | ||
| 28* | M6 | 141 | 311 | 217 | 12 | 54 |
| 198 | M6 | 3 | 93 | 46 | 68 | 28 |
| M6-1* | M6 | 101 | 103 | 161 | 35 | 43 |
| M6-3* | M6 | 159 | 324 | 184 | 5 | 91 |
| M6-4* | M6 | 152 | 279 | 170 | 5 | 48 |
| M6-5 | M6 | 39 | 63 | 109 | 6 | 81 |
| M6-6 | M6 | 9 | 84 | 158 | 26 | 16 |
| 219* | CML | 75 | 278 | 73 | 0 | 15 |
| 201* | RARS | 89 | 299 | 113 | 1 | 55 |
| 230* | RAEB | 197 | 726 | 233 | 11 | 32 |
| 236* | RAEB | 69 | 365 | 152 | 3 | 35 |
| 55* | RAEBT | 61 | 148 | 103 | 2 | 43 |
| Nonmalignant BM, mean ± SD | 23 ± 17 | 188 ± 66 | 62 ± 17 | |||
| Sample no. . | Diagnosis . | Expression (% K562) . | BM (%) . | |||
|---|---|---|---|---|---|---|
| TfR2-α . | TfR2-β . | TfR1 . | Blast . | Erythroid . | ||
| 28* | M6 | 141 | 311 | 217 | 12 | 54 |
| 198 | M6 | 3 | 93 | 46 | 68 | 28 |
| M6-1* | M6 | 101 | 103 | 161 | 35 | 43 |
| M6-3* | M6 | 159 | 324 | 184 | 5 | 91 |
| M6-4* | M6 | 152 | 279 | 170 | 5 | 48 |
| M6-5 | M6 | 39 | 63 | 109 | 6 | 81 |
| M6-6 | M6 | 9 | 84 | 158 | 26 | 16 |
| 219* | CML | 75 | 278 | 73 | 0 | 15 |
| 201* | RARS | 89 | 299 | 113 | 1 | 55 |
| 230* | RAEB | 197 | 726 | 233 | 11 | 32 |
| 236* | RAEB | 69 | 365 | 152 | 3 | 35 |
| 55* | RAEBT | 61 | 148 | 103 | 2 | 43 |
| Nonmalignant BM, mean ± SD | 23 ± 17 | 188 ± 66 | 62 ± 17 | |||
Expression of TfR1, TfR2-α, and TfR2-βmessenger RNA was analyzed by semiquantitative reverse-transcriptase polymerase chain reaction and shown as a percentage of the level detected in K562 cells. As reference, the mean ± SD of expression levels of nonmalignant marrow samples are shown in the bottom row (control).
Samples that had high levels of expression ofTfR2 mRNA (greater than 60% K562).